Aspen Neuroscience, Inc. has reported the completion of its initial public offering (IPO) and the effectiveness of its amended corporate governance documents. The company filed the report with the U.S. Securities and Exchange Commission on November 2, 2026.
The IPO involved the sale of 9,375,000 shares of common stock at a price to the public of $15.00 per share. The filing indicates that the gross proceeds to the company from this offering were approximately $140.6 million, before deducting underwriting discounts, commissions, and offering expenses.
In conjunction with the IPO, the company’s amended and restated certificate of incorporation and amended and restated bylaws became effective on November 2, 2026. These documents were approved by the company’s board of directors and stockholders to be effective immediately prior to the closing of the IPO.
Aspen Neuroscience is incorporated in Delaware and is listed on The Nasdaq Global Select Market under the trading symbol ASPE. The company’s principal executive offices are located at 10835 Road to the Cure, Suite 100, San Diego, CA 92121.
